Date: 28 Apr 2006
The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The aim of this study was to investigate the pharmacokinetics of loratadine and its active metabolite desloratadine after single-dose administration of loratadine as a conventional tablet, orally disintegrating tablet (smelt tablet) and a chewing gum formulation with and without the collection of saliva.
Twelve healthy male volunteers participated in a four-period cross-over trial evaluating the effect of dosage forms on the pharmacokinetics of a single dose of loratadine. Loratadine was administered as two 10-mg conventional tablet, two 10-mg smelt tablet, a 30-mg portion of medicated chewing gum without collection of saliva and a 30-mg portion of medicated chewing gum with collection of saliva. Blood samples were taken at predefined sampling points 0–24 h after medication, and the plasma concentrations of loratadine and desloratadine were determined by high-performance liquid chromatography. Each study period was separated by a wash-out period of at least 7 days.
The mean dose-corrected area under the plasma concentration-time curve extrapolated to infinity AUC(0−∞) for the chewing gum formulation was statistically significantly increased compared to the tablet formulation (geometric mean ratio: 2.68; 95%CI: 1.75–4.09). Desloratadine pharmacokinetic parameters from the chewing gum formulation were not statistically significantly different from the conventional tablet. Neither loratadine nor desloratadine pharmacokinetics of the smelt tablet formulation were statistically significantly different from the conventional tablet formulation. Plasma concentrations of desloratadine following the administration of loratadine as chewing gum with saliva collection were very low.
Our study showed that formulation of loratadine as a medicated chewing gum results in an almost threefold increase in relative bioavailability. This is most likely due to a bypass of first-pass metabolism as this study suggests that approximately 40% of the absorbed loratadine was absorbed via the oral mucosa.
Jacobsen J, Christrup LL, Jensen NH (2004) Medicated chewing gum: pros and cons. Am J Drug Delivery 2(2):75–88CrossRef
Bousquet E, Tirendi S, Bonina FP, Montenegro L, Bianchi A, Ciampini N (1992) Bioavailability of two formulations of acetylsalicylic acid gums. Pharmazie 47(8):607–609PubMed
Christrup LL, Bonde J, Eriksen H, Rasmussen SN, Rassing MR, Simonsen K (1988) Chewing gum as a drug delivery system III. Bioavailability of salicylamide administered in tablets and chewing gum. FARMACI, Sci Ed 16:6–14
Christrup LL, Bonde J, Rasmussen SN, Rassing MR (1990) Relative bioavailability of (+/−)-verapamil hydrochloride administered in tablets and chewing gum. Acta Pharm Nord 2(6):371–376PubMed
Hilbert J, Radwanski E, Weglein R, Luc V, Perentesis G, Symchowicz S, Zampaglione N (1987) Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol 27(9):694–698PubMed
Katchen B, Cramer J, Chung M, Gural R, Hilbert J, Luc V, Mortizen V, Dsouza R, Symchowicz S, Zampaglione N (1985) Disposition of C-14-Sch 29851 in Humans. Ann Allergy 55(2):393
Shannon IL, Segreto VA (1968) Saliva specific gravity. Tech Rep SAM-TR 1–8
Zhang YF, Chen XY, Zhong DF, Dong YM (2003) Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. Acta Pharmacol Sin 24(7):715–718PubMed
- The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers
European Journal of Clinical Pharmacology
Volume 62, Issue 6 , pp 437-445
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Biological availability
- Chewing gum
- Dosage forms
- Industry Sectors
- Author Affiliations
- 1. Institute of Public Health, Clinical Pharmacology, University of Southern Denmark, Winslowparken 19, 5000, Odense C, Denmark
- 2. Department of Biochemistry, Pharmacology and Genetics, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark